MedTrace Logo

Novel Alpha Glucan GI Tolerability Study (Loris Chronic)

NCT05142137 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-05-15

No results posted yet for this study

Summary

This study aims to evaluate the gastrointestinal tolerance of chronic consumption (7 days) of a novel alpha glucan compared to a rapidly available carbohydrate (glucose syrup).

Conditions

  • Healthy Volunteers

Interventions

DIETARY_SUPPLEMENT

Drinkable solution

The volunteers will consume 300 ml of liquid solution containing the novel alpha glucan or glucose syrup

Sponsors & Collaborators

  • Société des Produits Nestlé (SPN)

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-16
Primary Completion
2021-10-11
Completion
2021-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05142137 on ClinicalTrials.gov